Biolegend, 357306, APC anti-human Ganglioside GD2 Antibody, 100tests

Ganglioside GD2 is a sialic acid-containing glycosphingolipid involved in cell attachment to the extracellular matrix. Expression of GD2 in normal tissue is restricted to cells from the central nervous system, peripheral nerves, skin melanocytes, and mesenchymal stem cells. However GD2 is highly expressed by tumors of neuro-ectodermal origin such as melanomas, gliomas, neuroblastomas, and small cell lung carcinoma. GD2 has been proposed as a marker for some cancer stem cells.
100tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Neuroblastoma cell line LAN-1
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: Clone 14G2a is an isotype switch variant from parental hybridoma 14.18 (IgG3)1. Additional reported applications (for the relevant formats) include: inducing apoptosis and enhancing cytotoxicity of chemotherapeutic drugs in the neuroblastoma cell line 2. The LEAF™ or Ultra-LEAF™ purified antibody is recommended for use in cytotoxic and apoptotic studies (contact our custom solutions team). This clone has also been published as 14.G2a.
Application References(PubMed link indicates BioLegend citation): Mujoo K, et al. 1989. Cancer Res. 49:2857. (Cyt) Kowalczyk A, et al. 2009. Cancer Lett. 281:171. (Apop, Cyt) Battula VL, et al. 2012. J. Clin. Invest. 122:2066. (FC)
Product Citations: Taylor J, et al. 2023. Front Immunol. 14:1119350. PubMed Jaggupilli A, et al. 2022. Br J Cancer. 126:615. PubMed Barry WE, et al. 2019. Clin Cancer Res. 25:325. PubMed Zobel MJ, et al. 2020. J Immunother Cancer. 8:00. PubMed Raman S, et al. 2021. Cell Reports Medicine. 2(7):100344. PubMed Carlson PM, et al. 2021. J Immunol. 207:720. PubMed Voeller J, et al. 2019. J Immunother Cancer. 0.530555556. PubMed
RRID: AB_2563083 (BioLegend Cat. No. 357305) AB_2563084 (BioLegend Cat. No. 357306)
Distribution: Neurons, mesenchymal stem cells, highly expressed in tumors of neuro-ectodermal origin, such as melanomas, gliomas, neuroblastomas, and small cell lung carcinoma
Function: Cell attachment to extracellular matrix
Cell Type: Mesenchymal cells, Neurons
Biology Area: Apoptosis/Tumor Suppressors/Cell Death, Cell Adhesion, Cell Biology, Immunology, Neuroscience
Molecular Family: Adhesion Molecules
Antigen References: 1. Tarek N, et al. 2012. J. Clin. Invest. 122:3260. 2. Matthay KK, et al. 2012. Clin. Cancer Res. 18:2740. 3. Navid F, et al. 2010. Curr. Cancer Drug Targets. 10:200.
Gene ID: 2583
UniProt: View information about Ganglioside GD2 on UniProt.org
Clone: 14G2a
Regulatory Status: RUO
Other Names: Disialoganglioside GD2, Ganglioside G2
Isotype: Mouse IgG2a, κ